Shopping Cart
- Remove All
- Your shopping cart is currently empty
SBI-581 is an orally active, potent selective inhibitor of serine-threonine kinase TAO3, with an IC 50 of 42 nM. It effectively promotes the accumulation of TKS5α at RAB11-positive vesicles and inhibits the formation of invadopodia. Additionally, SBI-581 exhibits reasonable pharmacokinetics in mice when administered via IP injection, demonstrating significant antitumor activity [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,450 | 10-14 weeks | |
50 mg | $2,320 | 10-14 weeks | |
100 mg | $3,730 | 10-14 weeks |
Description | SBI-581 is an orally active, potent selective inhibitor of serine-threonine kinase TAO3, with an IC 50 of 42 nM. It effectively promotes the accumulation of TKS5α at RAB11-positive vesicles and inhibits the formation of invadopodia. Additionally, SBI-581 exhibits reasonable pharmacokinetics in mice when administered via IP injection, demonstrating significant antitumor activity [1]. |
In vitro | SBI-581 exhibits moderate selectivity, surpassing the majority of a wide array of kinases by a factor of 5 to 10 times [1]. |
In vivo | SBI-581, administered intraperitoneally at a dosage of 10 mg/kg, demonstrates favorable pharmacokinetics, characterized by a half-life (t 1/2) of 1.5 hours, an area under the curve (AUC) of 1202 hr*ng/mL, and a maximum concentration (Cmax) of approximately 2 μM [1]. |
Molecular Weight | 383.44 |
Formula | C24H21N3O2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.